Eli Lil­ly ousts CFO Josh Smi­ley af­ter 'i­nap­pro­pri­ate re­la­tion­ship' with em­ploy­ee, ap­points suc­ces­sor in Anat ...

5 years ago
People
Pharma

Learn­ing from oth­er­s' mis­takes, low-pro­file mi­croR­NA biotech looks to prove it­self in the clin­ic

5 years ago
R&D

Bris­tol My­ers Squibb pulls the cur­tain on PhI­II da­ta to back Op­di­vo in the ad­ju­vant set­ting

5 years ago
R&D

Mark Mal­lon wraps a short stint as CEO of Iron­wood, jump­ing out to pur­sue 'mul­ti­ple pas­sion­s' in the wake of set­backs

5 years ago
People

KalVista sees a win in PhII for the rare ge­net­ic dis­or­der HAE as it con­tin­ues to chart a post-Mer­ck course

5 years ago
R&D

Why mu­cos­al im­mu­ni­ty may be re­quired to end the pan­dem­ic

5 years ago
Biotech Voices

The SPAC at­tack has just be­gun. And the Richard Bran­son deal is just the tip of the biotech ice­berg

5 years ago
Financing

Lon­za of­floads spe­cial­ty in­gre­di­ents unit in $4.7B sale to Bain Cap­i­tal, Cin­ven in con­sol­i­da­tion around bio­phar­ma

5 years ago
Outsourcing
Manufacturing

Free­line Ther­a­peu­tics slams the brakes on gene ther­a­py tri­al plans as FDA seeks more clar­i­ty on man­u­fac­tur­ing

5 years ago
FDA+

Se­qens ma­jor­i­ty own­er look­ing to sell API mak­er amid record-high run in health­care val­u­a­tions: re­port

5 years ago
Deals
Manufacturing

Jasper's cell ther­a­py con­di­tion­ing agent shows promise in small study; Vi­iV's Ruko­bia sees ap­proval in Eu­rope

5 years ago
News Briefing

A syn­thet­ic lethal­i­ty play­er emerges in Chi­na, armed with lessons on un­drug­gable onco­gene from No­bel lau­re­ate's lab

5 years ago
Financing
Startups

For­mer Gale­na chief Mark Ahn back in hot wa­ter as DOJ lev­els in­sid­er trad­ing charges for con­sul­tant work

5 years ago
People
Pharma

IPO track­er: Af­ter an­oth­er three pric­ings bring to­tal raise close to $3B, de­buts ex­pect­ed to slow in short week

5 years ago
Financing

Covid-19 roundup: Sino­vac shot com­plete­ly pre­vents se­vere cas­es at 14-day mark, com­pa­ny says

5 years ago
Coronavirus

Ex-Bio­gen CEO Jim Mullen steps back to the helm of a biotech, and once again he has a crit­i­cal chal­lenge to con­front

5 years ago
People

Scoop: Deer­field and Dana-Far­ber forge clos­er ties to launch a new trans­la­tion­al can­cer re­search en­gine

5 years ago
Discovery

'Can't say no': Kite Phar­ma taps Frank Neu­mann as new head of clin­i­cal de­vel­op­ment

5 years ago
People

Re­gen­eron stum­bles in PhI Lib­tayo com­bo study as safe­ty con­cerns force sus­pen­sion

5 years ago
R&D

TG Ther­a­peu­tics scores con­di­tion­al FDA go-ahead for a drug it's pitch­ing as a safer PI3K

5 years ago
FDA+

South Africa side­lines As­traZeneca's vac­cine af­ter it failed to pro­tect against new vari­ant in a study, rais­ing ...

5 years ago
Coronavirus

Two years af­ter in­vestor pan­ic, Avro­bio touts 100% re­sponse as they look to chart a path to­ward ap­proval

5 years ago
R&D

The in­side sto­ry be­hind the fall of Lau­rie Glim­cher's big I/O start­up and the of­ten tense equa­tion of sci­ence and ...

5 years ago
Startups

Bris­tol My­ers Squibb earns long-await­ed FDA nod for liso-cel, join­ing short list of lym­phoma CAR-T win­ners

5 years ago
Pharma
FDA+
First page Previous page 737738739740741742743 Next page Last page
A service from the Financial Times